The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.
|Articles|April 7, 2015
YPrime Awarded Global Phase II Oncology Clinical Trial Which Will Utilize Proprietary eClinical Supply Forecasting Tool Combined With IRT
Advertisement
BOSTON and MALVERN, Pa., April 7, 2015 /PRNewswire/ -- Y-Prime, Inc., announced today that it has been awarded an international Phase II clinical trial to assess a new treatment for patients with Non-Small Cell Lung Carcinoma (NSCLC). This study will be conducted utilizing their proprietary
Throughout this trial, YPrime will be supporting world class selected sites to conduct the study with data driven metrics pulled from these tools. YPrime is dedicated to applying its leading edge eClinical technology to help forward unmet medical needs in the Biotech and Pharmaceutical industry.
"Our team is very pleased to continue helping Biotech and Pharmaceutical companies track patient activity and ensure the clinical supply chain runs smoothly with international studies. We have added significant value by playing a critical role in the successful integration of eClinical solutions for this virtual Biopharma organization." said Shawn Blackburn, President and Co-founder of YPrime.
Advertisement
Related to this article
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
AI agents in clinical operations acquire broader autonomous capability through expanded permissions, tools, memory, and delegated authority, requiring governance focused on whether effective capability has shifted outside approved boundaries rather than whether software has changed.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
Where AI Leads in Trial Design—and Where Humans Still Need To
3
Real-World Evidence Is Moving Upstream: Is the Data Infrastructure Ready?
4
The Data Inputs That Matter Most When Pressure-Testing a Protocol's Feasibility
5